ZYBERNO
Stock Report
Updated Aug 26, 2026

Exousia Bio, Inc. (LMMY)

OTC

$0.17

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
30.0/100
WEAK BUSINESS
Exousia Bio, Inc. (LMMY) scores 30/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-0.7%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Exousia Bio, Inc. (LMMY) stock report — Zyberno Score 30/100 (WEAK BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.17
Market Cap:$11.55M

Valuation Multiples (2)

P/B Ratio:0.53x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$11.56M

Price Action & Momentum (1)

% of 52-Week High:17.6%
B. Profitability Assessment

Margin Analysis (1)

Ebitda Margin:-5,426.7%

Yield Metrics (2)

Earnings Yield:$0.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-5.1%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:84.48x
Quick Ratio:84.48x
Cash Ratio:0.00x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:21,789,647.00
Cash And Cash Equivalents:0.00
Long Term Debt:$9.00K
Net Debt:$10.04K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $3.75K
Linear Growth: -5.1%
📊 Click to view full LMMY Revenue analysis & methodology →
Cost Of Revenue Ttm:$7.25K

Profitability Breakdown (2)

-$69.36K-$217.42K

Bottom Line Performance (3)

$498.00
Income Before Tax:$498.00
Ebitda Ttm:-203,501.00

Operating Expenses (5)

Operating Expenses:238,554.00
R And D Expense:0.00
Sga Expense:35,361.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:-5,426.7%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$22.05M
Current Assets:$22.05M
Ppe Net:670.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:261,023.00
Current Liabilities:261,023.00
Long Term Debt:$9.00K
Short Term Debt:$1.04K

Equity & Capital (3)

Equity:$21.79M
Retained Earnings:-$288.62K
Common Stock:100,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:212,302.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

$388.00$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:-$3.50K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:13,923.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):0.00
$0.00
Earnings Per Share Ttm:$0.00

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.00

Book Value & Capital (2)

Book Value Per Share:$0.31
Cash Per Share:-999.00

Dividend Policy (1)

Dividend Payout Ratio:0.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.00x
Working Capital Turnover Ttm:0.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:10,686.83
Cash Conversion Cycle:-12,684.83
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:70.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-5.1%
C. Company Profile & Context

Corporate Information (6)

Symbol:LMMY
Company Name:Exousia Bio, Inc.
Sector:Unknown
Industry:Education
Exchange:OTC
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:70.00M
Shares Outstanding Basic:70.00M
Shares Outstanding Diluted:16.76M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-26 22:29:44 UTC
Data Timestamp:2026-08-26T22:29:44.331814
Scroll to Top